Oxford, Prenetics Join Forces To Scale Award-Winning Rapid Molecular Testing Technology

The joint effort follows the successful acquisition of Oxsed, an Oxford University spin-out by Prenetics in 2020, to scale OxLAMP rapid COVID-19 test globally.
“The initial collaboration with Prenetics has exceeded all expectations, and their team led by Danny Yeung has been highly involved on a daily basis with our scientific developments,” said Professor Zhanfeng Cui of Oxford, who is also the Founding Director at OSCAR.

Rapid Screening Technology

The development of fast, accurate, and cheap COVID-19 detection products will decentralize the screening process and reduce the reliance on laboratories. The first OxLAMPTM RaViD Direct SARS-CoV-2 product was developed to facilitate rapid, portable, and accurate results in COVID-19 detection.

The OxLAMPTM test can deliver results in 20 minutes, with a sensitivity of 96% and a specificity of 99.9%, eliminating the need for laboratory processing. It has already received the CE-IVD mark in the EU and MHRA approval in the UK. Efforts are also made presently to submit it to the FDA for emergency authorization. The test is currently used at the London Heathrow airport and trialed at the Hong Kong International Airport to screen passengers.

New Center for the Development of Molecular Diagnostics

The collaboration would also establish a new Prenetics Innovation Technology Centre (ITC) for Advanced Molecular Diagnostics, which will be based in OSCAR, Oxford University’s first overseas center for research in physical and engineering sciences in Jiangsu Province, China. The center will attract experts from different domains, including bio-sensing, clinical virology, microbiology, and medical devices, to come together and develop new technologies for molecular diagnostics.

“Our new collaboration with Oxford University and OSCAR is our commitment to continually invest in R&D, and by establishing our own Innovation Technology Centre, we believe it will have profound breakthroughs in molecular diagnostics,” said Danny Yeung, Co-Founder and Group CEO of Prenetics.

“We also expect more top researchers to be based in Suzhou and in Oxford over the next 3 years into our technology center. The Oxford team of professors has been amazing, and I’m truly excited with our molecular diagnostic pipeline and the opportunity to decentralize laboratory testing globally,” he added.

Related Article: Illumina Enters Yet Another Oncology Partnership to Capitalize on its Pan-Cancer Assay

newsletter promo

©www.geneonline.news. All rights reserved. Collaborate with us: service@geneonlineasia.com

Leave a Reply

Your email address will not be published. Required fields are marked *